| 1 |
35143848 | Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. | 2022 May |
1 |
| 2 |
35512849 | The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese patients without Diabetes: A Systematic Review and Meta-Analysis. | 2022 May 5 |
1 |
| 3 |
32067559 | A Review of the Renoprotective Effects of Novel Antidiabetic Agents. | 2021 Feb |
1 |
| 4 |
33368612 | SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. | 2021 Mar |
1 |
| 5 |
33507658 | [News in Diabetology 2020]. | 2021 Jan 27 |
1 |
| 6 |
33606884 | Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. | 2021 Mar 23 |
1 |
| 7 |
33841337 | Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. | 2021 |
2 |
| 8 |
33852202 | Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study. | 2021 Aug |
1 |
| 9 |
33856655 | The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease. | 2021 May |
1 |
| 10 |
33880815 | Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. | 2021 Aug |
1 |
| 11 |
33975892 | SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. | 2021 May 11 |
1 |
| 12 |
34115034 | The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. | 2021 Jun 11 |
1 |
| 13 |
34116042 | Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells. | 2021 Sep 15 |
1 |
| 14 |
34144086 | GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. | 2021 Jul |
1 |
| 15 |
34705249 | Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis. | 2021 Nov |
1 |
| 16 |
31711841 | Intensification of medical management in type 2 diabetes: A real-world look at primary care practice. | 2020 Jan |
1 |
| 17 |
32308645 | GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. | 2020 |
1 |
| 18 |
32631337 | Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. | 2020 Jul 6 |
1 |
| 19 |
32700188 | Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. | 2020 Sep |
1 |
| 20 |
33041865 | Repurposing Antidiabetic Drugs for Cardiovascular Disease. | 2020 |
1 |
| 21 |
30099845 | Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development. | 2019 Mar |
1 |
| 22 |
30370686 | Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes. | 2019 Mar |
4 |
| 23 |
30394576 | Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. | 2019 Feb |
1 |
| 24 |
31021474 | Mechanisms of action of metformin with special reference to cardiovascular protection. | 2019 Oct |
1 |
| 25 |
31091948 | The role of GLP-1 receptor agonists and their fixed combination with insulin in the treatment of type 2 diabetes mellitus. | 2019 Spring |
1 |
| 26 |
31229399 | GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. | 2019 Aug |
1 |
| 27 |
31237921 | GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. | 2019 |
1 |
| 28 |
31440988 | Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. | 2019 Oct |
1 |
| 29 |
31766918 | Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. | 2019 Dec |
1 |
| 30 |
29559078 | [Metformin is a possible glucagon-like peptide 1 stimulator]. | 2018 Mar 19 |
3 |
| 31 |
29696037 | Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else? | 2018 Jan |
1 |
| 32 |
29760945 | Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study. | 2018 |
1 |
| 33 |
30084684 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. | 2018 Aug 7 |
1 |
| 34 |
30171481 | Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes. | 2018 Aug 31 |
1 |
| 35 |
30646315 | Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. | 2018 Dec 7 |
1 |
| 36 |
27860132 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. | 2017 Mar |
1 |
| 37 |
27862873 | Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. | 2017 Mar |
7 |
| 38 |
28143456 | Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. | 2017 Jan 31 |
1 |
| 39 |
28733377 | Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. | 2017 Aug |
1 |
| 40 |
29063276 | The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? | 2017 Oct 23 |
1 |
| 41 |
29082261 | Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes? | 2017 |
1 |
| 42 |
26587691 | An overview of new GLP-1 receptor agonists for type 2 diabetes. | 2016 |
1 |
| 43 |
27076180 | Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness. | 2016 Jun |
1 |
| 44 |
27216492 | Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. | 2016 Aug |
1 |
| 45 |
27304831 | Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. | 2016 |
1 |
| 46 |
27434443 | Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. | 2016 Jul 19 |
1 |
| 47 |
27627081 | [The effect of antidiabetic treatment on the bone of patients with type 2 diabetes]. | Fall 2016 |
1 |
| 48 |
27808040 | EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects. | 2016 Nov |
6 |
| 49 |
26034806 | Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects. | 2015 May |
1 |
| 50 |
26395850 | Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. | 2015 Nov |
1 |